Search
- Page Path
-
HOME
> Search
Review Article
- Systematic Review of Preclinical Evidence on Parenteral Administration of Schizonepeta Tenuifolia Sole Extract
-
Chaeheon Lee, Jihwan Choi, Ji Eun Choo, Ga Ram Yang, Hyung-Cheal Mun, Won Gun An, Cheol-Hyun Kim, Jaehyo Kim, Sangkwan Lee, Hongmin Chu
-
Perspect Integr Med. 2025;4(2):76-86. Published online June 23, 2025
-
DOI: https://doi.org/10.56986/pim.2025.06.002
-
-
Graphical Abstract
Abstract
PDF
Supplementary Material

- While steroids effectively control inflammation, their long-term use causes severe side effects, necessitating safer alternatives. Schizonepeta tenuifolia (S. tenuifolia) from the Lamiaceae family demonstrates potential as a natural therapeutic option through its anti-inflammatory and antiviral properties. This systematic review analyzed in vivo and in vitro studies of S. tenuifolia extract, focusing on non-oral administration routes to evaluate its therapeutic potential (n = 13). The extract effectively inhibited nuclear factor kappa-light-chain-enhancer of activated B cells and mitogen-activated protein kinase pathways, reduced inflammatory cytokine production, and showed antiviral effects. Additional benefits include wound healing and antiplatelet activity which enables targeted inflammation control without systemic immune suppression. The extract showed promise in conditions requiring targeted pathway modulation, such as inflammatory conditions needing selective cytokine inhibition, viral infections where interferon modulation is beneficial, and disorders with dysregulated mitogen-activated protein kinase signaling. These effects were achieved without the systemic immunosuppression typical of steroid treatments. While S. tenuifolia extract could serve as a safer alternative through non-oral administration routes, further research is needed to optimize extraction methods, identify key marker compounds, and determine optimal administration routes including topical administration and injectable formulations.
TOP